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Muscle degeneration in Duchenne muscular dystrophy (DMD) 
is exacerbated by increased oxidative stress and the endogenous 
inflammatory response, with a key role played by nuclear factor 
kappa-B (NF-κB) and other related factors such as tumor necrosis 
factor (TNF)-α and interleukin (IL)-6. However the time course 
of expression of these molecules and the relation with the amount 
of necrosis and regeneration have never been investigated.
 The expression of NF-κB, the cytokines TNF-α and IL-6 and the 
antioxidant enzyme glutathione peroxidase (GPx) was studied in 
muscle samples from 14 patients with DMD aged between 2 and 
9 years. Moreover a quantitative morphological evaluation was 
performed to evaluate necrotic and regenerative areas.
The highest percentage of necrosis was revealed within 4 years of 
age, with a significant negative correlation with age (p < 0.003), 
which paralleled to a significant decrement of regenerating area 
(p < 0.0004). We reported the novel observation that the number 
of NF-κB positive fibers and the NF-κB DNA-binding activity, 
revealed by EMSA, are high at two years of life and significantly 
decline with age (p < 0.0005 and p < 0.0001). The expression of 
TNF-α, IL-6 and GPx was upregulated in DMD muscles com-
pared to controls and significantly increased with age on real-
time PCR analysis (p < 0.0002; p < 0.0005; p < 0.03 respectively) 
and ELISA (p < 0.002; p < 0.02; p < 0.0001 respectively).
Since anti-inflammatory and anti-oxidant drugs are nowadays 
being translated to clinical studies in DMD, the reported insights 
on these therapeutic targets appear relevant. Further studies on 
the interactions among these pathways in different DMD phases 
and on the response of these cascades to treatments currently un-
der investigation are needed to better elucidate their relevance as 
therapeutic targets. 
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Introduction
Nuclear Factor Kappa-B (NF-κB) is a major transcrip-
tion factor expressed in a wide variety of cells and modu-
lating the cellular immune, inflammatory and proliferative 
responses (1). In unstimulated cells, NF-κB is inactive via 
interaction with its inhibitor protein (I-κB). NF-κB activa-
tion is regulated by the I-κB kinase (IKK) complex com-
posed of catalytic subunits, IKKα and IKKβ, and a regula-
tory subunit IKKγ/NEMO (2). Classical stimulatory signals 
such as proinflammatory cytokines (e.g. tumor necrosis 
factor [TNF]-α, interleukin [IL]-1β, IL-6) result in IKKβ-
mediated  site-specific  phosphorylation  and  subsequent 
degradation of I-κB. Loss of I-κB allows nuclear NF-κB 
entry and subsequent transcription of a diverse set of genes 
encoding growth factors, cytokines, chemokines, antiapop-
totic proteins and cell adhesion molecules (3). Moreover, 
NF-κB is an important mediator of redox-responsive gene 
expression  and  actively  involved  in  the  upregulation  of 
antioxidant enzymes, such as glutathione peroxidase and 
catalase, in response to oxidative stress (4). 
Duchenne muscular dystrophy (DMD) is a progres-
sive muscle wasting disorder leading to loss of ambula-
tion by thirteen years of age (5). The disease is caused 
by the absence of the protein dystrophin, which results in 
the loss of muscle membrane integrity. Consequently, this 
initial damage progresses to myofiber necrosis, phagocy-
tosis, infiltration of inflammatory cells and loss of muscle 
fibers with subsequent fibrosis and fat replacement lead-
ing to impaired muscle function (6). 
The  mechanisms  responsible  for  the  progression 
from initial membrane damage to pathological hallmarks 
of the dystrophic process have not been fully identified. 
There are many evidences that the initial myofiber dam-
age is exacerbated by the endogenous inflammatory re-
sponse (7-10) and increased oxidative stress (11). Inflam-
matory cells and cytokines may also further damage the 
sarcolemma resulting in myofiber necrosis rather than in 
the repair of minor membrane lesions (8).
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Our group demonstrated in DMD muscle immunore-
activity for the activated form of NF-κB in all regenerat-
ing fibers and in 20-40% of necrotic fibers. Western blot 
analysis of nuclear extracts and especially electrophoretic 
mobility shift assay (EMSA) analysis confirmed activa-
tion of NF-κB (12). In the murine model of DMD, the 
mdx mouse, a skeletal muscle-specific activation of NF-
κB has been demonstrated even before the onset of dys-
trophic damage (13). We have also reported that oxidative 
stress/lipid peroxidation and NF-κB activation occur in 
mdx mice and that their inhibition significantly amelio-
rate functional, morphological and biochemical param-
eters (14-16).
Nevertheless  the  NF-κB  contribution  to  dys-
trophic damage in humans has been poorly investigat-
ed (10, 12, 17, 18) and the time-course of its activation 
remains unstudied. Therefore the aim of this study is to 
define the NF-κB activation and the NF-κB-related genes 
expression profiling in different phases of DMD course. 
This study might also help to choose the most effective 
time-frame to administer pharmacological modulators of 
NF-κB activity in future clinical trials.
Materials and methods
We studied vastus lateralis muscle samples from 14 
patients with DMD aged between 2 and 9 years. The di-
agnosis was based on clinical features, muscle biopsy 
with dystrophin analysis by immunocytochemistry and 
study of the dystrophin gene. Fourteen muscle samples 
taken from age-matched normal subjects (2-9 years), un-
dergoing orthopedic surgery, were tested as controls. All 
individuals or their parents had given informed consent 
for the scientific use of the muscle biopsy. The Medical 
School Ethical Committee, University of Messina, au-
thorized the study.
Histological studies
All specimens were frozen in isopentane cooled in 
liquid nitrogen and stored at – 70° C. Transverse cryostat 
sections (10 μm) were stained with hematoxylin-eosin, 
and then examined by a blinded observer, using the Ax-
ioVision 2.05 image analysis system equipped with Axi-
ocam camera scanner (Zeiss, Munchen, Germany). The 
following two areas were recognized with intermingled 
distribution on three different sections: (i) necrotic fib-
ers, identified by pale cytoplasm and phagocytosis; (ii) 
regenerating fibers, identified by small size, basophilic 
cytoplasm  and  central  nuclei.  The  results  were  ex-
pressed as the ratio of the area occupied by necrotic or 
regenerating fibers divided by the total surface area as a 
percentage. 
Immunocytochemistry
Seven-  μm-thick  transverse  cryostat  sections  from 
vastus lateralis muscles were incubated for 120 minutes 
at 37°C in rabbit polyclonal antibody against phospho-
NF-κB p65 subunit (Ser276) (1:50; Cell Signaling Tech-
nology, Beverly, MA). It selectively binds to the NF-κB 
p65 only when phosphorylated at serine 276, ie, it is acti-
vated and can then undergo nuclear translocation.
Nonspecific binding of immunoglobulin was blocked 
with  5%  normal  horse  serum.  Immunodetection  was 
performed using a biotin-avidin system (DAKO, Milan, 
Italy) followed by horseradish peroxidase staining with 
3,3- diaminobenzidine tetrahydrochloride. 
NF-κB DNA-binding activity by electrophoresis mobility 
shift assay (EMSA)
Isolation of nuclear proteins in approximately 50 mg 
of frozen muscle was performed according to elsewhere 
detailed methods (12). Twenty micrograms of nuclear 
extract were incubated for 30 min at room temperature 
with  50  fmol  of  biotin-end-labeled  45-mer  double-
strand NF-κB oligonucleotide from the HIV long ter-
minal  repeat,  5′-TTGTTACAAGGGACTTTCCGCTG
GGGACTTTCCAGGAGGCGTGGG-  3′  containing  2 
(underlined) NF-κB binding sites. Both complimentary 
oligos were end-labeled separately and then annealed 
prior to use. Binding reaction mixtures were prepared in 
a final volume of 20 μL HEPES buffer containing 1 mg 
double-strand poly dI/dC, 10% glycerol, 100 mM Mg-
Cl2 and 1% Nonidet P-40. The shift was performed by 
LightShift™ Chemiluminescent EMSA Kit (Pierce, Mi-
lan, Italy), according to the manufacturer’s instructions. 
Competitive  assays  were  also  performed  by  addition 
of 50-fold excess of unlabeled probe to nuclear extract 
at room temperature for 10 min before the addition of 
the labeled probe. Bound complexes were separated on 
7.5% nondenaturating polyacrylamide gels, blotted onto 
nylon membrane and visualized on Kodak X-ray film 
(Kodak, Milan, Italy) by autoradiography. The results 
are expressed as relative integrated intensity compared 
with normal controls and internal positive controls, con-
sidering exposure time, background levels, and known 
protein concentration of an Epstein– Barr virus nuclear 
antigen-1 extract, with its consensus sequence provided 
with  the  Light-Shift  Chemiluminescent  kit  (Pierce), 
which was used as EMSA control.
RNA isolation and real-time PCR
Total RNA was extracted from each muscle biopsy 
specimen  using  TRIzol  reagent,  followed  by  DNase  I 
treatment (Invitrogen, Carlsbad, CA). The RNA quality 
and quantity were checked respectively on agarose gel S. Messina et al.
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and by spectrophotometry. 3 µg of total RNA from each 
sample was reverse-transcribed by Archive kit (Applied 
Biosystems, Milan, Italy). Generated cDNA was used 
as template for real-time quantitative PCR analysis us-
ing gene expression products according to the manu-
facturer’s  recommendations.  For  each  real-time  PCR 
reaction, we used 2.5µl of cDNA in a total volume of 
50 µl. We performed reactions with a 7300 Sequence 
Detection System apparatus (Applied Biosystems) to 
quantitatively compare the mRNA levels. IL-6, glutath-
ione peroxidase (GPx), TNF-α and β-actin (as an en-
dogenous control) assays were obtained from Applied 
Biosystems. Real time PCR was performed in duplicate 
with 2X TaqMan Universal PCR Master Mix. The ther-
mal cycling conditions consisted of one cycle each for 
2 min at 50°C and 10 min at 95°C, and 40 cycles for 
15s at 95°C and 1 min at 60°C. All gene expression 
levels were normalized to β-actin mRNA level, which 
was determined simultaneously in the same tube. The 
comparative cycle threshold (Ct) method was used to 
analyse the data by generating relative values of the 
amount of target cDNA. Relative quantification (RQ) 
for these genes was expressed as fold variation over 
control, and was calculated by the ΔΔCt method, using 
control samples as calibrators.
ELISA
GPx, TNF-α and IL-6 gene expressions were evalu-
ated for protein expression using ELISA. Muscle levels 
of GPx, TNF-α and IL-6 were measured using conven-
tional double sandwich ELISA kits from Invitrogen Inc. 
(Carlsbad, CA). Assays were performed according to the 
manufacturer’s instructions and expressed as ng or pg/mg 
of non collagen protein.
Statistical analysis
Mann-Whitney  U  and  ANOVA  tests  (StatView 
software, version 5.0.1) were used for group compari-
sons. The relationship between variables was studied 
using Pearson’s correlation coefficient and Fisher two-
tailed test. A level of significance of p < 0.05 was con-
sidered. 
Results
A pathological consequence of the absence of dys-
trophin from the sarcolemmal membrane is the altered 
mechanical and signaling functions which contribute 
to  membrane  fragility,  necrosis,  inflammation,  and 
progressive muscle wasting (19). The time course of 
DMD pathology during early disease phases and the 
contribution of inflammatory pathways is an understud-
ied area. To better detail these aspects we performed 
quantitative morphological evaluation of vastus latera-
lis muscle in patients of different ages. It revealed the 
highest percentage of necrosis within 4 years of age 
being the mean value 5.1 (SD ± 1.1), whereas it was 
2.7 (SD ± 0.8) in DMD patients between 5 and 9 years 
(p < 0.001). The percentage of necrosis had a signifi-
cant negative correlation with age (r: - 0.75; p < 0.003; 
Fig. 1A). 
In DMD, the regeneration process is stimulated by 
muscle necrosis and fails to keep pace with the repeated 
cycles of degeneration. Therefore, the imbalance between 
Figure 1. Morphological evaluation of quadriceps muscles: graphs showing the correlation between area with necrot-
ic (A) and regenerating (B) fibers expressed as percentage and patients’ age.Activation of NF-κB pathway in Duchenne muscular dystrophy: relation to age
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muscle damage and muscle repair leads to a loss of mus-
cle fibers and an increase in the amount of fibrosis. In 
keeping with this evidence in our experiment, we showed 
that the decrease of necrosis paralleled to a significant 
decrement of the percentage of regenerating area with age 
(r: - 0.82; p < 0.0004; Fig. 1 B).
No immunoreactivity for NF-κB was found in mus-
cle specimens from normal controls (Fig. 2 A). In DMD 
patients NF-κB immunoreactivity was seen in the nu-
clei of the majority of regenerating fibers seen on serial 
hematoxylin-eosin sections and also in the nuclei of few 
apparently normal fibers. NF-κB immunoreactivity was 
also observed in a low percentage of fibers with features 
of necrosis and phagocytosis (Fig. 2 B). Following the 
trend of the regenerating fibers, we showed a significant 
decrease in the number of NF-κB positive fibers with age 
(r:-0.81; p < 0.0005; Fig. 2 C).
NF-κB  DNA  binding  activity  revealed  by  EMSA 
was absent in normal controls and with wide variability 
among patients ranging from 70 to 15 (integrated inten-
sity, arbitrary units) in relation to the increase in age (r:-
0.87; p < 0.0001; Fig. 2 D,E). 
We found that the expression of GPx was upregulated 
in DMD muscles compared to controls and had a significant 
positive correlation with age on real-time PCR analysis (r: 
0.59, p < 0.03, Fig. 3A) and confirmed by ELISA (r: 0.89; 
p < 0.0001, Fig. 4A). Similarly, TNF-α and IL-6 expression 
was augmented in dystrophic muscles and significantly in-
creased with age as demonstrated with real-time PCR (r: 
0.89; p < 0.0002 and r: 0.86, p < 0.0005, respectively; Fig. 
3B,C) and confirmed by ELISA (r: 0.76; p < 0.002 and r: 
0.62; p < 0.02, respectively Fig. 4B,C). Moreover real-time 
PCR analysis revealed that GPx, TNF-α and IL-6 mRNA 
levels were increased respectively 97-, 1.8- and 25.9-fold 
(mean values) in muscles belonging to DMD patients with-
in 4 years of age, whereas 537-, 27,7- and 148-fold (mean 
values) in DMD patients between 5 and 9 years, compared 
to control muscles (p < 0.001).
Figure 2. Representative images of NF-kB-immunolocalization in control (A) and in DMD muscle (B) scale bar 50 μm, 
graph showing the correlation between the number of NF-kB-positive fibers expressed as percentage and patients’ 
age (C). Electrophoretic mobility shift assay of muscular NF-kB binding activity: representative autoradiograms (D) and 
graph showing the correlation betweenthe NF-kB binding activity expressed as integrated intensity (arbitrary units) and 
patients’ age (E).S. Messina et al.
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Discussion
Membrane  defects  and  mechanical  injury  are  im-
portant  factors  promoting  dystrophic  disease  pathol-
ogy, but they do not fully explain DMD disease onset 
and progression (20, 21). Aberrant intracellular signaling 
cascades that regulate both inflammatory and immune 
processes  contribute  substantially  to  the  degenerative 
process (10, 13, 22, 23). Our group has extensively in-
vestigated  the  mechanisms  underlying  the  dystrophic 
process  in  mdx  mice,  demonstrating  that  a  cross-talk 
between oxidative stress/lipid peroxidation and NF- κB 
activation occurs, in turn triggering inflammatory cas-
cades involving TNF-α, IL-1 β, mitogen-activated pro-
tein kinases (MAPKs) and cyclooxygenase (COX) and 
5-lipoxygenase  (5-LOX)  and  contributing  to  muscle 
damage. Finally modulation of these cascades, obtained 
through NF- kB inhibitors, led to a significant decrease 
of muscle necrosis and increase of regeneration, improv-
ing mdx mice functional performances (14-16). Several 
other studies supported our results showing that NF-κB 
inhibition, through IKK β depletion (24) or ablation of 1 
allele of the p65 NF-κB subunit (17) improved muscle 
force, decreased necrosis and facilitated muscle regen-
eration in mdx mice and after muscle damage. Further-
more, specific pharmacological inhibition of IKK also 
resulted in improved muscle function and pathology in 
mdx mice (17). 
NF-κB signalling pathway has been shown to be ab-
errantly activated in DMD muscle during early disease 
stages (17, 25). However the time course of NF-κB ex-
pression over time and the relation with the amount of 
necrosis and regeneration have never been investigated. In 
our study we reported the novel observation that in DMD 
patients the number of NF-κB positive fibers and the NF-
Figure 3. Real-time PCR: graphs showing the correlation between GPx (A), TNF-α (B) and IL-6 (C) expression,   
expressed as fold change compared to controls, and patients’ age.Activation of NF-κB pathway in Duchenne muscular dystrophy: relation to age
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partially explained by the diminished inflammatory and 
necrotic stimuli, but also by the exhaustion of the regen-
erative spurt leading to connective and adipose tissue re-
placement.
It has been pointed out that numerous components of 
chronic inflammatory response, such as TNF-α, IL-1β, 
IL-6, modulated by NF-κB, are overexpressed in dys-
trophic muscle (7, 16, 23, 30) and their increased expres-
sion precedes the onset of dystrophic changes (13). TNF-α 
levels have been shown to be approximately 1,000 times 
higher in serum of DMD patients than controls (31). Sev-
eral lines of evidence suggested TNF-α role in promoting 
muscle wasting, and its inhibition has been demonstrated 
to have beneficial effects in mdx mice (7, 14-16, 30). In 
our study, we confirmed previous findings of a marked 
enhancement  of  TNF-α  and  IL-6  expression  in  DMD 
muscle compared to controls and showed their increase 
with age. Although oxidative stress, TNF-α and IL-6 are 
κB DNA-binding activity are high at two years of life and 
significantly decline with age, being very low by the 9th 
year of age. The decrement in NF-κB DNA-binding ac-
tivity in muscle was very pronounced with a reduction of 
nearly 80% between patients of 2 and 9 years of age. 
The same trend was monitored in the percentage of 
necrotic fibers that was around 6% at 2 years of age and 
significantly declined up to 2-3% at 9 years. This is in keep-
ing with previously reported morphological data showing 
a typical dystrophic pattern in DMD patients since few 
months of age and a subsequent age-related decline (26). 
Moreover, it has been reported that the most evident pres-
ence of infiltrating mononuclear cells occurs between the 
age of 2-8 years (27, 28) and the peak of mast cell infiltra-
tion, implicated in the initiation and progression of muscle 
lesions, takes place by the age of 3 years (29). 
As expected the decrement of necrosis was mirrored 
by a decrease of regeneration over time. This could be 
Figure 4. ELISA: graphs showing the correlation between GPx (A), TNF-α (B) and IL-6 (C) expression and patients’ age.S. Messina et al.
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known to be potent NF-κB inducers, in our study the ex-
pression of NF-κB tended to diminish over time. Whereas 
downregulation of NF-κB signaling could be explained 
by the decrease of regenerating and necrotic fibers with 
age that are replaced by adipose and connective tissue, 
the increase of TNF-α and Il-6 in older DMD muscles 
could account for the amount of cytochines produced by 
adipocytes (32, 33).
Although the role of oxidative stress in contributing 
to dystrophic damage has been extensively investigated, 
controversy still remains concerning whether oxidative 
stress is a necessary precondition for death of dystrophic 
muscle or is a consequence of pathology that does not ad-
vance the disease (34). Several studies focused on the lev-
els of oxidative stress markers in dystrophic muscle (34), 
but a time-course of these parameters in DMD also in 
relation to muscle pathology has never been defined. In 
this study we confirmed the increase of oxidative stress in 
dystrophic muscles compared to controls as proved by the 
augmented expression of GPx, most likely in a compen-
satory attempt to counterbalance it, and demonstrated for 
the first time its increase with age despite the decrement 
of muscle necrosis. 
Since anti-inflammatory and anti-oxidant drugs are 
nowadays being translated to clinical studies in DMD, the 
definition of the time-course expression of these thera-
peutic targets is crucial.
Our group has recently started a pilot trial with fla-
vocoxid, a NF-κB inhibitor shown to be effective in mdx 
mice (16), in young ambulant DMD patients and the data 
obtained in the present study have been of help to define 
in 4-6 years range the more effective time frame for treat-
ment administration. 
Further studies on the interactions among these path-
ways in different DMD phases and on the response of 
these cascades to treatments currently under investigation 
are needed to better elucidate their relevance as therapeu-
tic targets. 
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